Q3 2017 Earnings Forecast for Spark Therapeutics, Inc. (ONCE) Issued By Leerink Swann

Spark Therapeutics, Inc. (NASDAQ:ONCE) – Investment analysts at Leerink Swann lifted their Q3 2017 earnings estimates for Spark Therapeutics in a report issued on Tuesday. Leerink Swann analyst J. Schwartz now forecasts that the biotechnology company will post earnings of ($1.64) per share for the quarter, up from their previous estimate of ($1.96). Leerink Swann also issued estimates for Spark Therapeutics’ Q4 2017 earnings at ($1.64) EPS, FY2017 earnings at ($7.31) EPS and FY2018 earnings at ($4.56) EPS.

Several other research analysts also recently issued reports on the company. Chardan Capital reaffirmed a “buy” rating and set a $100.00 price objective on shares of Spark Therapeutics in a report on Friday. Raymond James Financial, Inc. began coverage on Spark Therapeutics in a research note on Thursday. They issued an “outperform” rating and a $96.00 price target on the stock. BMO Capital Markets set a $89.00 price target on Spark Therapeutics and gave the company a “buy” rating in a research note on Tuesday. Cowen and Company reissued a “buy” rating and issued a $95.00 price target on shares of Spark Therapeutics in a research note on Tuesday. Finally, Jefferies Group LLC reissued a “buy” rating and issued a $95.00 price target on shares of Spark Therapeutics in a research note on Tuesday. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and eighteen have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $88.81.

COPYRIGHT VIOLATION WARNING: “Q3 2017 Earnings Forecast for Spark Therapeutics, Inc. (ONCE) Issued By Leerink Swann” was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be read at https://sportsperspectives.com/2017/10/13/q3-2017-earnings-forecast-for-spark-therapeutics-inc-once-issued-by-leerink-swann.html. Spark Therapeutics (NASDAQ:ONCE) last issued its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.89) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.75) by ($0.14). The firm had revenue of $1.48 million for the quarter, compared to analyst estimates of $1.33 million. Spark Therapeutics had a negative net margin of 962.72% and a negative return on equity of 59.74%. The firm’s revenue for the quarter was up 14.7% compared to the same quarter last year. During the same quarter last year, the business posted ($1.04) earnings per share.

In related news, insider Katherine A. High sold 5,000 shares of the company’s stock in a transaction on Tuesday, September 26th. The shares were sold at an average price of $86.16, for a total value of $430,800.00. Following the completion of the sale, the insider now owns 215,000 shares in the company, valued at approximately $18,524,400. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Hospital Of Philade Children’s sold 1,000,000 shares of the company’s stock in a transaction on Thursday, September 21st. The shares were sold at an average price of $84.63, for a total transaction of $84,630,000.00. Following the completion of the sale, the director now owns 3,928,707 shares of the company’s stock, valued at approximately $332,486,473.41. The disclosure for this sale can be found here. In the last 90 days, insiders sold 1,333,195 shares of company stock valued at $109,070,506. 7.30% of the stock is owned by corporate insiders.

A number of hedge funds have recently added to or reduced their stakes in the business. Principal Financial Group Inc. increased its holdings in Spark Therapeutics by 0.3% during the 1st quarter. Principal Financial Group Inc. now owns 38,752 shares of the biotechnology company’s stock worth $2,067,000 after purchasing an additional 122 shares in the last quarter. Cornerstone Capital Management Holdings LLC. increased its holdings in Spark Therapeutics by 3.2% during the 2nd quarter. Cornerstone Capital Management Holdings LLC. now owns 11,089 shares of the biotechnology company’s stock worth $662,000 after purchasing an additional 342 shares in the last quarter. Ameritas Investment Partners Inc. increased its holdings in Spark Therapeutics by 23.6% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,040 shares of the biotechnology company’s stock worth $122,000 after purchasing an additional 389 shares in the last quarter. Nationwide Fund Advisors increased its holdings in Spark Therapeutics by 2.5% during the 1st quarter. Nationwide Fund Advisors now owns 17,298 shares of the biotechnology company’s stock worth $923,000 after purchasing an additional 414 shares in the last quarter. Finally, KCG Holdings Inc. increased its holdings in Spark Therapeutics by 9.4% during the 1st quarter. KCG Holdings Inc. now owns 6,247 shares of the biotechnology company’s stock worth $333,000 after purchasing an additional 538 shares in the last quarter. Hedge funds and other institutional investors own 77.84% of the company’s stock.

About Spark Therapeutics

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Earnings History and Estimates for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply